Your browser doesn't support javascript.
loading
Predicting subgroup treatment effects for a new study: Motivations, results and learnings from running a data challenge in a pharmaceutical corporation.
Bornkamp, Björn; Zaoli, Silvia; Azzarito, Michela; Martin, Ruvie; Müller, Carsten Philipp; Moloney, Conor; Capestro, Giulia; Ohlssen, David; Baillie, Mark.
Afiliação
  • Bornkamp B; Global Drug Development, Novartis Pharma AG, Basel, Switzerland.
  • Zaoli S; Global Drug Development, Novartis Pharma AG, Basel, Switzerland.
  • Azzarito M; Global Drug Development, Novartis Pharma AG, Basel, Switzerland.
  • Martin R; Global Drug Development, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Müller CP; Data Digital, Beyond Conception GmbH, Altendorf, Switzerland.
  • Moloney C; Global Drug Development, Novartis Pharma AG, Dublin, Ireland.
  • Capestro G; Global Drug Development, Novartis Pharma AG, Basel, Switzerland.
  • Ohlssen D; Global Drug Development, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Baillie M; Global Drug Development, Novartis Pharma AG, Basel, Switzerland.
Pharm Stat ; 23(4): 495-510, 2024.
Article em En | MEDLINE | ID: mdl-38326967
ABSTRACT
We present the motivation, experience, and learnings from a data challenge conducted at a large pharmaceutical corporation on the topic of subgroup identification. The data challenge aimed at exploring approaches to subgroup identification for future clinical trials. To mimic a realistic setting, participants had access to 4 Phase III clinical trials to derive a subgroup and predict its treatment effect on a future study not accessible to challenge participants. A total of 30 teams registered for the challenge with around 100 participants, primarily from Biostatistics organization. We outline the motivation for running the challenge, the challenge rules, and logistics. Finally, we present the results of the challenge, the participant feedback as well as the learnings. We also present our view on the implications of the results on exploratory analyses related to treatment effect heterogeneity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Fase III como Assunto / Motivação Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Pharm Stat Assunto da revista: FARMACOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Fase III como Assunto / Motivação Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Pharm Stat Assunto da revista: FARMACOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suíça